The performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings.
Anxiety
Community setting
Depression
EQ-5D-3L
Hospital
Screening
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
22
10
2020
accepted:
04
03
2021
entrez:
20
3
2021
pubmed:
21
3
2021
medline:
3
6
2021
Statut:
epublish
Résumé
To examine the performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings compared to other patient-reported screening tools. Data from a prospective cohort of patients discharged from general internal medicine wards from two hospitals in Edmonton, Alberta were used in this study. Two waves of measurements (discharge and 90-days post-discharge) were analyzed. The performance of the EQ-5D-3L was compared to other self-report screening tools: Generalized Anxiety Disorder 2-item questionnaire was used to categorize anxiety symptoms into absent (< 3) and present (≥ 3), and the Patient Health Questionnaire 9-items was used to categorize depressive symptoms by two severity cut-points: no (< 10) vs. mild (≥ 10), and no (< 15) vs. moderate-severe (≥ 15). Performance of EQ-5D-3L in screening for anxiety and depressive symptoms was evaluated using receiver operating curve (ROC) analysis. Average age of participants (n = 493) was 62.9 years (SD 18.6); 51% were female. At discharge, 30.0% screened positive for mild and 12.8% for moderate-severe depressive symptoms, while 27.6% screened positive for anxiety symptoms. For co-morbid symptoms, 17.1% screened positive for anxiety and any depressive symptoms, while 10.8% for anxiety and moderate-severe depressive symptoms. While the EQ-5D-3L had limited screening ability in hospital, the anxiety/depression dimension performed well in the community setting (90-days post-discharge) in screening for anxiety (area under ROC 0.79), depressive symptoms (any: 0.78, moderate-severe: 0.84), and a combination of both (any: 0.86; moderate-severe: 0.91). The EQ-5D-3L anxiety/depression dimension could be a useful tool in screening for anxiety and depressive symptoms in community settings compared to other self-report screening tools. The usefulness of the EQ-5D-3L as a screening tool in other settings and populations is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
To examine the performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings compared to other patient-reported screening tools.
METHODS
METHODS
Data from a prospective cohort of patients discharged from general internal medicine wards from two hospitals in Edmonton, Alberta were used in this study. Two waves of measurements (discharge and 90-days post-discharge) were analyzed. The performance of the EQ-5D-3L was compared to other self-report screening tools: Generalized Anxiety Disorder 2-item questionnaire was used to categorize anxiety symptoms into absent (< 3) and present (≥ 3), and the Patient Health Questionnaire 9-items was used to categorize depressive symptoms by two severity cut-points: no (< 10) vs. mild (≥ 10), and no (< 15) vs. moderate-severe (≥ 15). Performance of EQ-5D-3L in screening for anxiety and depressive symptoms was evaluated using receiver operating curve (ROC) analysis.
RESULTS
RESULTS
Average age of participants (n = 493) was 62.9 years (SD 18.6); 51% were female. At discharge, 30.0% screened positive for mild and 12.8% for moderate-severe depressive symptoms, while 27.6% screened positive for anxiety symptoms. For co-morbid symptoms, 17.1% screened positive for anxiety and any depressive symptoms, while 10.8% for anxiety and moderate-severe depressive symptoms. While the EQ-5D-3L had limited screening ability in hospital, the anxiety/depression dimension performed well in the community setting (90-days post-discharge) in screening for anxiety (area under ROC 0.79), depressive symptoms (any: 0.78, moderate-severe: 0.84), and a combination of both (any: 0.86; moderate-severe: 0.91).
CONCLUSIONS
CONCLUSIONS
The EQ-5D-3L anxiety/depression dimension could be a useful tool in screening for anxiety and depressive symptoms in community settings compared to other self-report screening tools. The usefulness of the EQ-5D-3L as a screening tool in other settings and populations is warranted.
Identifiants
pubmed: 33741011
doi: 10.1186/s12955-021-01731-x
pii: 10.1186/s12955-021-01731-x
pmc: PMC7977278
doi:
Types de publication
Journal Article
Multicenter Study
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
96Références
Palliat Med. 1999 Sep;13(5):399-407
pubmed: 10659112
J Am Geriatr Soc. 2014 Mar;62(3):495-9
pubmed: 24512099
J Clin Psychiatry. 2004;65 Suppl 13:20-6
pubmed: 15384933
J Hosp Med. 2017 Feb;12(2):118-125
pubmed: 28182810
Health Qual Life Outcomes. 2010 May 05;8:47
pubmed: 20444251
J Gen Intern Med. 2000 May;15(5):311-20
pubmed: 10840266
S Afr Med J. 1992 Dec;82(6):441-2
pubmed: 1465699
Br J Psychiatry. 1975 Apr;126:346-53
pubmed: 1148567
JAMA. 1995 Nov 15;274(19):1511-7
pubmed: 7474219
Depress Anxiety. 2006;23(2):77-82
pubmed: 16411185
Trends Psychiatry Psychother. 2017 Jan-Mar;39(1):12-18
pubmed: 28403318
Arch Gen Psychiatry. 2012 May;69(5):506-14
pubmed: 22566583
Health Technol Assess. 2014 May;18(34):vii-viii, xiii-xxv, 1-188
pubmed: 24857402
Gen Hosp Psychiatry. 2014 May-Jun;36(3):318-24
pubmed: 24630892
Soc Sci Med. 2020 Nov;265:113323
pubmed: 32919196
Prim Care Companion CNS Disord. 2011;13(2):
pubmed: 21977354
Med Decis Making. 2019 May;39(4):379-392
pubmed: 31161860
J R Soc Med. 1989 Jul;82(7):410-2
pubmed: 2585427
Arch Phys Med Rehabil. 2012 Oct;93(10):1838-45
pubmed: 22555007
Evid Based Med. 2007 Oct;12(5):149
pubmed: 17909240
Age Ageing. 2012 Mar;41(2):148-54
pubmed: 22236655
Eur J Health Econ. 2013 Jul;14 Suppl 1:S1-3
pubmed: 23900659
CMAJ. 2012 Feb 21;184(3):E191-6
pubmed: 22184363
Arch Fam Med. 1995 Mar;4(3):211-9
pubmed: 7881602
Health Qual Life Outcomes. 2004 May 05;2:20
pubmed: 15128456
J Geriatr Cardiol. 2012 Jun;9(2):197-208
pubmed: 22916068
Med Care. 2016 Jan;54(1):98-105
pubmed: 26492214
Aust N Z J Psychiatry. 1991 Sep;25(3):322-9
pubmed: 1845255
N Engl J Med. 2010 Dec 30;363(27):2611-20
pubmed: 21190455
J Clin Psychiatry. 2010 Mar;71(3):235-8
pubmed: 20122368
CMAJ. 2015 Aug 11;187(11):799-804
pubmed: 26009583
Depress Anxiety. 2002;16(4):162-71
pubmed: 12497648
Health Rep. 2013 Sep;24(9):3-9
pubmed: 24258361
Depress Anxiety. 2000;12(1):21-9
pubmed: 10999242
J Gen Intern Med. 1997 Jul;12(7):439-45
pubmed: 9229283
Qual Life Res. 2007 Jun;16(5):749-54
pubmed: 17294286
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
Int J Psychiatry Med. 1994;24(2):115-20
pubmed: 7960419
Science. 1988 Jun 3;240(4857):1285-93
pubmed: 3287615
Med Clin North Am. 2001 May;85(3):579-96
pubmed: 11349474